Catalyzed by Covid-19, the accelerated uptake of virtual services within neuroscience has set in motion a reimagining of future healthcare pathways. The new post-pandemic reality is a hybrid virtual/in-person approach for many neurological and psychiatric conditions - driving rapid regulatory change, reduced delivery costs, and improved patient access.
CAR T-cell therapies space is complex, highly competitive, and quickly evolving. Add the pandemic to the mix and the logistical, reimbursement, and pricing landscape grows even more complicated. In this in-depth paper we research the current state of CAR T-cell therapies and speculate on the factors currently making the largest impact - China, Commercialization, and COVID-19. Read more for a comprehensive, well-researched take on the space.
Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussion series on Navigating Market Disruption. Episode two is Leading in a crisis. Rita and Pete will discuss why focus and remaining agile during and after a crisis are essential for success. Executives looking for practical advice on how to balance agility and governance processes will find this discussion valuable.
Join Peter Hempshall, Deallus CEO, and Rita Numerof, President of Numerof & Associates for Episode 2 of their discussion series - Leading in a crisis. This episode will explore topics around how leaders can manage effectively during a crisis and continue to deliver value for their customers, their organizations, and for themselves. Any business leader eager to explore tactics, best practices, and learning experiences gained from leading in times of uncertainty will find value in this episode.
Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussions on ‘Navigating Market Disruption After Covid-19’. This OnDemand webinar discusses how the pandemic has accelerated market shifts already in play, disrupting current business models, and dramatically altering how pharma business will be done in the future.
As the COVID-19 pandemic continues to impact patients, healthcare systems, and global economic outlooks, we focus on the key considerations and strategies for pharma companies when the data generation for possible therapies is becoming increasingly complex to analyze. There are several COVID-19 treatment and vaccine databases containing an aggregation of publicly-available information from validated sources detailing treatments and vaccines currently in development.